591 related articles for article (PubMed ID: 34802253)
1. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
Martinez FA; Serenelli M; Nicolau JC; Petrie MC; Chiang CE; Tereshchenko S; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Ponikowski P; Sabatine MS; DeMets DL; Dutkiewicz-Piasecka M; Bengtsson O; Sjöstrand M; Langkilde AM; Jhund PS; McMurray JJV
Circulation; 2020 Jan; 141(2):100-111. PubMed ID: 31736328
[TBL] [Abstract][Full Text] [Related]
4. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
6. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
7. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
8. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
9. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
McMurray JJV; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD;
Eur J Heart Fail; 2019 Nov; 21(11):1402-1411. PubMed ID: 31309699
[TBL] [Abstract][Full Text] [Related]
10. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
[TBL] [Abstract][Full Text] [Related]
11. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
[TBL] [Abstract][Full Text] [Related]
12. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
Selvaraj S; Fu Z; Jones P; Kwee LC; Windsor SL; Ilkayeva O; Newgard CB; Margulies KB; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Lanfear DE; Nassif ME; Javaheri A; Mentz RJ; Kosiborod MN; Shah SH;
Circulation; 2022 Sep; 146(11):808-818. PubMed ID: 35603596
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV; Solomon SD; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Anand IS; Bělohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett JG; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Petrie MC; Vinh PN; Schou M; Tereshchenko S; Verma S; Held C; DeMets DL; Docherty KF; Jhund PS; Bengtsson O; Sjöstrand M; Langkilde AM;
N Engl J Med; 2019 Nov; 381(21):1995-2008. PubMed ID: 31535829
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
[TBL] [Abstract][Full Text] [Related]
17. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
McMurray JJV; DeMets DL; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD;
Eur J Heart Fail; 2019 May; 21(5):665-675. PubMed ID: 30895697
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
19. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61.
Patel SM; Morrow DA; Bellavia A; Berg DD; Bhatt DL; Jarolim P; Leiter LA; McGuire DK; Raz I; Steg PG; Wilding JPH; Sabatine MS; Wiviott SD; Braunwald E; Scirica BM; Bohula EA
Eur J Heart Fail; 2024 Feb; 26(2):260-269. PubMed ID: 38131261
[TBL] [Abstract][Full Text] [Related]
20. Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial.
Kang DH; Park SJ; Shin SH; Hwang IC; Yoon YE; Kim HK; Kim M; Kim MS; Yun SC; Song JM; Kang SM
Circulation; 2024 Jun; 149(24):1865-1874. PubMed ID: 38690659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
